Voorbeelden van het gebruik van Trabectedin in het Engels en hun vertalingen in het Nederlands
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Mg trabectedin.
It contains the active substance trabectedin.
Yondelis trabectedin.
Trabectedin can have genotoxic effects.
Effects of other substances on trabectedin.
Trabectedin is genotoxic both in vitro
Yondelis contains the active substance trabectedin.
Trabectedin should not be used during pregnancy.
There is no specific antidote for extravasation of trabectedin.
Trabectedin has immunomodulatory effects that inhibit TAMs.
There is no specific antidote for trabectedin currently available.
Trabectedin crossed the placenta when administered to pregnant rats.
The study assessed the efficacy and safety of trabectedin vs.
Thus the trabectedin extraction ratio can be considered moderate.
There is limited data on the effects of trabectedin overdose.
Trabectedin does not induce or inhibit major cytochrome P450 enzymes.
Preclinical data have demonstrated that trabectedin is a substrate to P-gp.
Yondelis 0.25 mg powder for concentrate for solution for infusion Trabectedin.
Renal elimination of unchanged trabectedin in humans is low less than 1.
Trabectedin extravasation may cause tissue necrosis requiring debridement.
Myelosupression and hepatoxicity were identified as the primary toxicity for trabectedin.
The concomitant use of trabectedin with alcohol must be avoided see section 4.5.
The inter-patient variability of the population estimate for plasma clearance of trabectedin was 51% and intra-patient variability was 28.
Hypersensitivity to trabectedin or to any of the excipients listed in section 6.1.
Trabectedin pharmacokinetic profile is consistent with a multiple-compartment disposition model.
The effects of race and ethnicity on trabectedin pharmacokinetics have not been studied.
Trabectedin must not be used in patients with creatinine clearance<
Grade 3-4 dyspnoea reported as trabectedin related occurred in 2% of the patients.
The patients received the trabectedin dose of 1.2 mg/m2 recommended for Japanese patients 1.2 mg/m2 once every 3 weeks q3wk 24-h.
Patients may develop a potentially severe injection site reaction when trabectedin is administered through a peripheral venous line.